Tazepam Tazepam is a methyltransferase inhibitor indicated for the treatment of: • Adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not candidates for complete resection.

LuciTaze Tablets Simple Instructions

Please use under the guidance of a physician

Product Name: LuciTaze

Manufacturer: Lucius Pharmaceuticals (Laos) Co., Ltd.

Chinese name: Tazestat tablets

English name: Tazemetostat tablets

Drug approval number: 09 L 1211/24

 

【Indications】

LuciTaze is a methyltransferase inhibitor indicated for the treatment of:

• Adults and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not candidates for complete resection.

• Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.

• Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

 

【Usage and Dosage】

• The recommended dose is 800 mg orally twice daily, with or without food.

 

【Specification】

200 mg/tablet, 56 tablets/box.

 

【 Contraindications 】

none.

 

【 Warnings and precautions 】

• Secondary Malignancies: LuciTaze is associated with an increased risk of secondary malignancies, including T-cell lymphoblastic lymphoma, myelodysplastic syndrome, and acute myeloid leukemia. Monitor patients on an ongoing basis for the development of secondary malignancies.

• Embryo-Fetal Toxicity: May cause fetal harm. Advise patients of the potential risk to the fetus and to use effective non-hormonal contraceptives.

 

【Adverse Reactions】

• The most common adverse reactions (≥20%) in patients with epithelioid sarcoma are pain, fatigue, nausea, decreased appetite, vomiting, and constipation.

• The most common adverse reactions (≥20%) in patients with follicular lymphoma were fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, and abdominal pain.

 

【Drug Interactions】

• Strong and Moderate Cytochrome P450 (CYP)3A Inhibitors: Avoid coadministration of strong and moderate CYP3A inhibitors with LuciTaze. If coadministration of moderate CYP3A inhibitors cannot be avoided, reduce the dose of LuciTaze.

• Strong and moderate CYP3A inducers: Avoid coadministration with LuciTaze.

 

【Use by specific groups】

• Lactation: Breastfeeding is not recommended.

 

【Storage】

Storage temperature is 20℃ to 25℃ (68℉ to 77℉), short-distance transportation is allowed between 15℃ to 30℃ (59℉ to 86℉). Protect from moisture.